1. Home
  2. Resources
  3. COVID-19 Treatments, Therapeutics & Test to Treat Information

COVID-19 Treatments, Therapeutics & Test to Treat Information

Information on this page is a general overview of therapeutic treatments. In no way is the following information meant to replace or override the medical advice received from a licensed physician. Always check with your healthcare provider for a professional assessment on treatments that are right for you.

About Treatments and Therapeutics

COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on healthcare facilities, and even save lives.

According to the revised NIH treatment guidelines, oral antiviral medications and monoclonal antibody treatment should be administered as soon as possible after a positive SARS-CoV-2 test, but no later than 5 days after symptom onset (for oral antivirals) and no later than 10 days after symptom onset (for monoclonal antibodies).

Test to Treat

The federal government has launched a program for you to receive end-to-end care for COVID-19. Now you can come to one location, receive a COVID-19 test or a reading of your at-home COVID-19 test and promptly get an assessment for treatment from an on-site health care provider.

What is Test to Treat?
Test to treat is federal program initiative to begin bridging the gap between patients testing positive for COVID-19 and receiving oral antiviral medications. This program is intended to provide one central location for a patient to get tested, evaluated after their diagnosis, and receive oral antiviral medication should they fit the EUA requirements for receiving the medication.

Where are the San Bernardino Department of Public Health (SBDPH) COVID-19 Test to Treat locations? (Including days of operation and hours)?

The health centers below are providing test to treat services to assigned IEHP and uninsured patients following California Department of Health Care Services (DHCS) guidelines. To set up an appointment, call 1-800-722-4777.

Adelanto Health Center
11336 Bartlett Ave., Ste.11
Adelanto, CA 92301
Monday – Friday, 8 a.m. – 5 p.m.

Hesperia Health Center
16453 Bear Valley Rd.
Hesperia, CA 92345
Monday – Friday, 8 a.m. – 5 p.m.

Ontario Health Center
150 E. Holt Blvd.
Ontario, CA 91761
Monday – Friday, 8 a.m. – 5 p.m.

San Bernardino Health Center
606 E. Mill St.
San Bernardino, CA 92415
Monday – Friday, 8 a.m. – 5 p.m.

How will it work? Which treatments will be available?

Each patient will need a positive COVID-19 test, which can be administered on site at the Test to Treat facility or brought in by the patient for assessment. The patient will then need to be evaluated by a healthcare provider on site who can provide a prescription for the appropriate treatment. The patient will then be given either Paxlovid or Legevrio (molnupiravir) and will follow the directions given by the healthcare provider or pharmacist. To schedule an appointment at one of San Bernardino County’s Public Health Clinics please call 1-800-722-4777.

Available Treatments
Paxlovid: Can be prescribed to positive COVID-19 patients 12 years of age and older.
Molnupiravir: Can be prescribed to positive COVID-19 patients 18 years of age and older.

OptumServe Test to Treat

The SMARTER Plan is the next phase of California’s COVID-19 response.  Included in this plan is providing opportunity for testing and treatments to patients regardless of insurance status or ability to pay. In an effort to have equitable access to end to end care for COVID-19, California Department of Public Health (CDPH) has partnered with OptumServe to open additional federally funded Test to Treat Sites across San Bernardino County.

Make an appointment at an OptumServe site near you. Use the Test to Treat Locator to ensure the site is offering this service.

If you have any questions, please call the OptumServe call center at (866) 284-8788.

When will it be available?
Test to treat is available now! To find a location near you use the Test to Treat Locator. A call center is also available at 1-800-232-0233 (TTY 1-888-720-7489) to get help in English, Spanish, and more than 150 other languages – 8:00 am to midnight ET, 7 days a week. The Disability Information and Access Line (DIAL) is also available to specifically help people with disabilities access services. To get help, call 1-888-677-1199, Monday-Friday from 9:00 am to 8:00 pm ET or email DIAL@usaginganddisability.org.

Do I need insurance?

Patients will not be charged for the cost of COVID-19 medications. At this time California Department of Health Care Services (DHCS) covers COVID-19 related services including all medical care, at no cost to the patient until the end of the public health emergency.

However uninsured patients do hold the responsibility for applying for the COVID-19 Uninsured Group prior to receiving treatments.

Additionally the Medi-Cal program is still available for low-income California residents and will cover treatments services and medical care.

  • COVID-19 Uninsured Group Program
  • Medi-Cal Health Insurance Enrollment

If I have questions, who do I call or email? Is there a website for reference?

How to Find a Test to Treat Site?
To find Test to Treat locations near you, view  COVID-19 Test to Treat Locator.

You can call 1 (800) 232-0233 to get additional support in English, Spanish and 150+ languages.

Available 7 days a week from 8 a.m. to midnight EST

The Disability Information and Access Line is available to help people with disabilities access services via phone at (888) 677-1199 or email DIAL@usaginganddisability.org.

Available Monday – Friday from 9 a.m. – 8 p.m. ET

Pre-Exposure Prophylaxis (PrEP) Monoclonal Antibody Treatment (Preventative/at-risk)

Effective December 9, 2021, The Food & Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for EVUSHELD for pre-exposure prophylaxis (PrEP). Please discuss a medical evaluation and/or referral with your healthcare provider.

What is Pre-exposure Prophylaxis (PrEP)?
Pre-exposure prophylaxis (PrEP) is medicine taken to protect or prevent vulnerable individuals from getting COVID-19.

Who is eligible to receive a PrEP monoclonal antibody treatment?
Individuals who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2 AND

  • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or,
  • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

How is the PrEP treatment administered?
Evusheld is administered by a healthcare professional. One dose of EVUSHELD consists of two intramuscular injections immediately given one after another. The best timing for you to receive additional doses of Evusheld, if needed, is not known right now, because this depends on which SARS-CoV-2 variants will be present in the future.
Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of EVUSHELD™ (tixagevimab co-packaged with cilgavimab) for Coronavirus Disease 2019 (COVID-19)

What should I tell my doctor before receiving EVUSHELD?
Tell your healthcare about all of your medical conditions, including if you:

  • Have any allergies
  • Have low numbers of blood platelets (which help blood clotting), a bleeding disorder, or  are taking anticoagulants (to prevent blood clots)
  • Have had a heart attack or stroke, have other heart problems, or are at high-risk of cardiac (heart) events
  • Are pregnant or plan to become pregnant
  • Are breastfeeding
  • Have any serious illness
  • Are taking any medicines (prescription, over-the-counter, vitamins, or herbal products)

Monoclonal Antibody Treatment (Symptomatic/ at-risk and positive)

Monoclonal Antibody Treatment (Symptomatic/ at-risk and positive)
If you test positive for COVID-19 and would like to receive a monoclonal antibody (mAb) infusion, please discuss a medical evaluation and/or referral with your healthcare provider.

Who is eligible to receive a mAb infusion?
If you are at risk for serious COVID-19 and you have tested positive for COVID-19 or have been in close contact with someone who has tested positive, you may want to consider a monoclonal antibody (mAb) treatment. You may qualify for this promising COVID-19 treatment depending on your age, health history, and how long you have had symptoms. You do not need to have symptoms or test positive to qualify for mAb treatment if you are at high risk for serious COVID-19.

How are monoclonal antibodies administered?
Monoclonal antibodies are administered by a healthcare professional via an intravenous infusion typically, although they may be administered subcutaneously also. The process takes approximately 30 minutes for the infusion. When making an appointment however, allow up to three hours for the full visit to allow monitoring time following your infusion.

What should I tell my doctor healthcare provider before receiving monoclonal antibody treatments?
Tell your healthcare about all of your medical conditions, including if you:

  • Have any allergies
  • Have had a serious allergic reaction to sotrovimab or to any of its ingredients
  • Are pregnant or plan to become pregnant
  • Are breastfeeding or plan to breastfeed
  • Have any serious illnesses
  • Are taking and medicines (prescription, over-the-counter, vitamins, or herbal products)

Oral Antivirals (Symptomatic/ at-risk and positive)

On December 22 and 23, 2021, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) that allow 2 new oral antiviral agents to be used in this patient population: ritonavir-boosted nirmatrelvir (Paxlovid) and Lagevrio (molnupiravir).

The CDC has issued a Health Advisory to update the public of the potential of recurring COVID-19 symptoms or COVID-19 Rebound after taking Paxlovid. COVID-19 Rebound is a brief return of symptoms or a new positive viral test after having tested negative. With the current research available, Paxlovid continues to be the recommended treatment for at risk COVID-19 patients.

If you have experienced COVID-19 Rebound or the recurrence of symptoms, current recommendations are:

  • Follow the CDC Isolation Guidelines and re-isolate for at least 5 days
  • Consult with your healthcare provider, especially if your COVID-19 Rebound symptoms persist or worsen

Click here to see the full CDC Health Advisory announcement

Who is eligible to receive oral antiviral treatment for COVID-19?
Both Paxlovid and Lagevrio (molnupiravir) are available by prescription only. These antiviral pills won’t be available by prescription to everyone, though, and the eligibility criteria differs for each.

Pfizer’s Paxlovid will be available to people who:

  • Have tested positive for COVID-19 and have not yet been admitted to the hospital and
  • Are high risk for developing severe COVID-19 and
  • Are 12 years of age or older (and at least 88 pounds)

Modified dosing of Paxlovid is now available for COVID-19 patients with moderate renal or kidney impairment. Talk to your healthcare provider to see if you are eligible to receive Renal Paxlovid.

Merck’s Lagevrio (molnupiravir) will be available to people who:

  • Have tested positive for COVID-19 and have not yet been admitted to the hospital and
  • Are high risk for developing severe COVID-19 and
  • Have no alternative FDA-authorized COVID-19 treatment options accessible to them or that are clinically appropriate for them and
  • Are 18 years of age or older

Your doctor will help you understand whether you’re eligible to receive an oral antiviral, as well as which option is best for you.

How is Paxlovid prescribed?
Paxlovid consists of 2 medicines: nirmatrelvir and ritonavir.

  • Take 2 pink tablets of nirmatrelvir with 1 white tablet of ritonavir by mouth 2 times each day (in the morning and in the evening) for 5 days.
  • For each dose, take all 3 tablets at the same time.
  • If you have kidney disease, talk to your healthcare provider. You may need a different dose.

What should I tell my healthcare provider before I take Paxlovid?
Tell your healthcare provider if you:

  • Have any allergies
  • Have liver or kidney disease
  • Are pregnant or plan to become pregnant
  • Are breastfeeding a child
  • Have any serious illnesses
  • Are taking any medicines (prescription, over-the-counter, vitamins, herbal supplements, or hormonal contraceptives).

Refer to Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Paxlovid for Coronavirus Disease 2019 (COVID-19) for complete instruction and further information.

How is Merck’s Lagevrio (molnupiravir) prescribed?

  • Take Lagevrio (molnupiravir) exactly as your healthcare provider instructed.
  • Take 4 capsules of Lagevrio (molnupiravir) every 12 hours (for example, at 8 am and at 8 pm)
  • Take Lagevrio (molnupiravir) for 5 days. It is important that you complete the full 5 days of treatment with Lagevrio (molnupiravir). Do not stop taking Lagevrio (molnupiravir) before you complete the full 5 days of treatment, even if you feel better.

What should I tell my healthcare provider before I take Lagevrio (molnupiravir)?
Tell your healthcare provider if you:

  • Have any allergies
  • Are breastfeeding or plan to breastfeed
  • Are pregnant or plan to become pregnant
  • Have any serious illnesses
  • Are taking any medicines (prescription, over-the-counter, vitamins, herbal supplements, or hormonal contraceptives).

Tell your healthcare provider if you are pregnant or plan to become pregnant before taking this medication. If you are at childbearing age and ability (both male and female), this medication may not be right for you. Your healthcare provider may do a pregnancy test before starting treatment with Lagevrio (molnupiravir). Always discuss the potential risks and benefits with your doctor before deciding what treatment option is best for you.

Refer to Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Lagevrio (molnupiravir) For Coronavirus Disease 2019 (COVID-19) for complete instruction and further information.

Treatment Facilities

Therapeutic treatments are shipped countywide. Patients should consult with their respective physician or care provider before receiving COVID-19 treatments.

The link below will show you all facilities that have received COVID-19 therapeutics. However, patients should not contact locations directly. Always consult with your physician for eligibility to receive any COVID-19 Treatments.

COVID-19 Therapeutics Locator

Pre-Exposure Monoclonal Antibody Treatment (Preventative)

  • AstraZeneca’s Evusheld (AZD7442)

Monoclonal Antibody Treatment (Symptomatic)

  • Lilly’s Bebtelovimab

Lilly COVID Hotline: 1-855-545-5921

Oral Antivirals

  • Pfizer’s Paxlovid
  • Merck’s Lagevrio (molnupiravir)